Urologic Imaging

Should You Order Imaging for Asymptomatic Nonmuscle Invasive Bladder Cancer Surveillance?

·
Should You Order Imaging for Asymptomatic Nonmuscle Invasive Bladder Cancer Surveillance?

A 68-year-old male is in your urology clinic for his 12-month surveillance visit after a transurethral resection of a low-grade, nonmuscle invasive bladder cancer (NMIBC). He feels well, denies any hematuria or voiding symptoms, and his recent urine cytology was negative. Your office cystoscopy is scheduled for today. As you prepare, you consider ordering a routine pelvic ultrasound or a CT scan “just to be sure” nothing is missed. Is this the right move? For this specific clinical scenario—an asymptomatic patient with no new risk factors undergoing surveillance for NMIBC—the American College of Radiology (ACR) provides clear guidance. Imaging studies, including US pelvis (bladder) and CT Urography, are designated as **Usually not appropriate**, shifting the focus to direct visualization and cytology as the primary surveillance tools.

Who Fits This Clinical Scenario?

This guidance applies specifically to patients who have completed initial treatment for nonmuscle invasive bladder cancer (stages Ta, T1, or Carcinoma in Situ) and are now in the surveillance phase. The key inclusion criteria for this workflow are:

  • A confirmed history of NMIBC that has been treated (e.g., via transurethral resection).
  • The patient is currently asymptomatic, with no new signs like gross hematuria, flank pain, or significant lower urinary tract symptoms.
  • There are no new, specific risk factors to suggest disease progression or upper tract involvement.

It is crucial to distinguish this low-risk surveillance population from other clinical situations where imaging is vital. This guidance does not apply if the patient presents with new symptoms. For instance, a patient with new-onset gross hematuria would fit a different scenario (Nonmuscle invasive bladder cancer with symptoms or risk factors), where imaging to evaluate the entire urothelial tract is often necessary. Similarly, patients with a history of muscle-invasive bladder cancer, with or without cystectomy, follow a completely different and more intensive imaging surveillance protocol to monitor for local recurrence and distant metastases.

What Diagnoses Are You Monitoring For in This Scenario?

While imaging is not the primary tool in this context, the goal of surveillance is to detect several potential events early. The diagnostic strategy, led by cystoscopy and cytology, is designed to identify recurrence or progression before it becomes a more significant clinical problem.

Intravesical Recurrence: This is the most common event in NMIBC surveillance. The majority of recurrences are nonmuscle invasive themselves and can be managed with repeat resection and intravesical therapy. Flexible cystoscopy provides direct visualization of the bladder mucosa and is highly sensitive for detecting new papillary tumors.

Progression to Muscle-Invasive Disease: This is the most critical outcome to prevent. Progression signifies a tumor invading the muscularis propria of the bladder wall, which dramatically changes prognosis and requires aggressive, multimodal therapy like radical cystectomy. While imaging can detect large, invasive masses, cystoscopy and biopsy remain the gold standard for staging.

Upper Tract Urothelial Carcinoma (UTUC): Patients with bladder cancer are at a lifetime risk for developing tumors in the lining of the ureters or renal pelvis. However, the incidence of asymptomatic UTUC in a low-risk NMIBC patient is very low. The low pre-test probability is a key reason why routine upper tract imaging is not recommended in this specific asymptomatic group.

Metastatic Disease: The risk of distant spread from NMIBC, particularly low-grade disease, is extremely low. Therefore, routine systemic imaging with chest, abdomen, and pelvis CT scans is not warranted for surveillance in this population, as the diagnostic yield is negligible and does not justify the radiation exposure.

Why Imaging Is Usually Not Appropriate for This Presentation

The core principle behind the ACR’s “Usually not appropriate” rating for all imaging modalities in this scenario is that the diagnostic yield is too low to justify the risks, costs, and potential for false positives. The established standard of care—office cystoscopy and urine cytology—is more sensitive and specific for the most likely event: intravesical recurrence.

Cystoscopy and Cytology are the Primary Tools: White light or blue light (enhanced) cystoscopy allows for direct, real-time visualization of the bladder lining, capable of detecting even small papillary tumors or suspicious flat lesions (like carcinoma in situ) that would be invisible on cross-sectional imaging. Urine cytology complements this by detecting abnormal shed cells, which can sometimes identify high-grade disease missed on cystoscopy.

Why Alternatives Are Rated Lower:

  • CT Urography (CTU) without and with IV contrast: While CTU is the gold standard for evaluating the upper tracts for UTUC, it is rated Usually not appropriate here. The rationale is risk-benefit. For an asymptomatic NMIBC patient, the probability of finding an upper tract tumor is very low. This low yield does not outweigh the significant cumulative radiation dose (☢☢☢☢ 10-30 mSv) from repeated surveillance scans over many years. The risk of radiation-induced secondary malignancy becomes a valid concern.
  • US pelvis (bladder): Ultrasound is also rated Usually not appropriate. Although it is inexpensive and involves no radiation (O 0 mSv), its sensitivity for detecting NMIBC recurrence is poor. It cannot reliably identify small tumors, flat lesions like CIS, or differentiate post-treatment scarring from small recurrences. It is significantly inferior to direct visualization with cystoscopy.

In summary, for the asymptomatic NMIBC patient, imaging offers little to no advantage over the established surveillance protocol of cystoscopy and cytology. It introduces unnecessary radiation (CT), cost, and the potential for incidental findings that lead to further, often fruitless, workups.

What’s Next? The Standard Surveillance Workflow

The downstream workflow for this patient population is driven by the results of cystoscopy and urine cytology, not by routine imaging.

  • If Cystoscopy and Cytology are Both Negative: The patient continues on their risk-stratified surveillance schedule. This typically involves cystoscopy every 3-6 months for the first two years, then with increasing intervals if they remain disease-free. No imaging is indicated.
  • If Cystoscopy is Positive (Visible Tumor): The next step is a transurethral resection of bladder tumor (TURBT) in the operating room. This procedure serves to both re-stage the disease and treat the recurrence. Pre-operative imaging is generally not required unless there is a high suspicion of muscle invasion based on the tumor’s appearance.
  • If Cystoscopy is Negative but Cytology is Positive for High-Grade Cells: This is a concerning finding that suggests an occult high-grade tumor. The workflow involves a thorough search for the source, which may include bladder biopsies of normal-appearing mucosa, prostatic urethral biopsies, and potentially upper tract imaging (now indicated due to a new risk factor). This patient would now move into the symptomatic/risk factor scenario.

Pitfalls to Avoid (and When to Escalate)

The primary pitfall in this scenario is performing low-yield surveillance imaging out of habit or “reassurance.” This can lead to unnecessary radiation exposure, costs, and a cascade of follow-up tests for incidental findings. Another pitfall is becoming complacent with cystoscopy; a meticulous examination of the entire bladder is essential at every visit. Finally, do not dismiss positive high-grade cytology, even with a normal-appearing bladder; it is a red flag that requires a diligent workup. If a patient develops new gross hematuria, flank pain, or if cytology becomes positive, escalate immediately to a more comprehensive evaluation that includes upper tract imaging, typically with CT Urography.

Related ACR Topics and Tools

This article focuses on a single, common clinical scenario. For a comprehensive overview of imaging across all bladder cancer surveillance situations, from NMIBC with symptoms to post-cystectomy follow-up, please consult our parent guide. For additional decision support, the tools below can help you apply ACR guidance and communicate with patients.

Frequently Asked Questions

If all imaging is ‘Usually not appropriate’, what is the standard surveillance protocol for NMIBC?

The standard of care for surveillance in asymptomatic, low-risk NMIBC patients is a combination of office-based flexible cystoscopy and urine cytology. The frequency of these tests is determined by the patient’s individual risk stratification (low, intermediate, or high risk) based on tumor grade and stage.

Is there ever a role for upper tract imaging like CT Urography in NMIBC surveillance?

Yes, but not for routine screening in asymptomatic, low-risk patients. Upper tract imaging with CT Urography becomes appropriate if a patient develops new risk factors, such as positive high-grade urine cytology with a normal cystoscopy, new-onset gross hematuria, or unilateral flank pain.

Why isn’t a non-radiation modality like MRI or ultrasound a good substitute for cystoscopy?

Neither MRI nor ultrasound has the sensitivity to detect small or flat urothelial tumors (like carcinoma in situ) as effectively as direct visualization with cystoscopy. They cannot reliably distinguish post-treatment scarring from small recurrences. Cystoscopy remains the gold standard for examining the bladder lining.

What if my patient is anxious and requests a scan for reassurance?

This is a common situation that requires patient education. Explain that for their specific condition, cystoscopy is a more effective test than a CT or ultrasound. You can also discuss the concept of diagnostic yield and explain that the risks of routine imaging (like radiation from CT and the potential for incidental findings) outweigh the very low chance of finding anything significant in the absence of symptoms.

Does this ‘no imaging’ recommendation apply to high-risk NMIBC (e.g., T1 high-grade)?

Yes, this guidance applies to all asymptomatic NMIBC patients in surveillance, regardless of risk group. While high-risk patients undergo more frequent cystoscopy and may receive intravesical BCG therapy, routine imaging is still not recommended unless they develop symptoms or specific indications like positive cytology with a negative cystoscopy. The primary surveillance tool remains cystoscopy.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 21, 2026